培美曲塞与顺铂对非小细胞肺癌患者血清microRNA-19、IL-27、TGF-β1、MMP2的影响

目的 培美曲塞联合顺铂治疗非小细胞肺癌（NSCLC）患者的效果及对患者血清microRNA-19、白细胞介素-27（IL-27）、转化生长因子-β1（TGF-β1）、基质金属蛋白酶2（MMP-2）水平的影响。方法 选取河南科技大学第一附属医院收治的97例NSCLC患者，收治时间2014年1月-2016年2月，随机分为两组，其中观察组49例，采用培美曲塞+顺铂治疗，对照组48例，采用吉西他滨+顺铂治疗。连续化疗2个周期后进行临床疗效评价，并比较两组血清microRNA-19、IL-27、TGF-β1、MMP2水平。结果 治疗前，观察组和对照组的血清microRNA-19、IL-27、TGF-β1、MMP2水平比较，差异无统计学意义；治疗后，观察组患者的血清microRNA-19、TGF-β1、MMP2水平显著的低于对照组（P<0.05），血清IL-27水平显著的高于对照组（P<0.05）。观察组患者的缓解率42.86%显著的高于对照组的22.92%，差异有统计学意义（P<0.05）；观察组的总有效率87.76%高于对照组的79.17%，但差异无统计学意义。治疗过程中，观察组和对照组的各种不良反应发生率比较，差异均无统计学意义。结论 培美曲塞联合顺铂治疗NSCLC患者能显著的改善血清microRNA-19、TGF-β1、MMP2水平，从而达到提高治疗效果的目的。

Effects of pemetrexed and cisplatin on serum levels of microRNA-19, IL-27, TGF-1 and MMP2 in patients with NSCLC

Objective Pemetrexed combined with cisplatin in the treatment of non-small cell lung cancer (NSCLC) patients and the effects of microRNA-19 on serum interleukin -27 (IL-27), transforming growth factor beta 1 (TGF-beta 1), matrix metalloproteinase 2 (MMP-2) level of influence. Methods A total of 97 cases of NSCLC patients in our hospital from January 2014, to February 2016, of which 49 cases were treated with pemetrexed + cisplatin treatment (observation group), 48 patients were treated with gemcitabine plus cisplatin treatment (control group), continuous chemotherapy clinical curative effect was evaluated after 2 cycles. Results Before treatment, observation group and control group, serum microRNA-19 IL-27, TGF beta 1 and MMP2 levels, the difference was not statistically significant. After treatment, the observation group of patients with serum microRNA-19, TGF beta 1 and MMP2 were significantly lower than that of control group (P<0.05), the serum level of IL-27 was significantly higher than that of control group (P<0.05). The remission rate of observation group 42.86% was significantly higher than that of control group 22.92% (P<0.05). Efficiency of observation group was 87.76%,which higher than that of the control group 79.17%, but the difference was not statistically significant. In the course of treatment, observation group and control group all kinds of adverse reaction rate comparison, difference there was no statistical significance. Conclusion Pemetrexed combined with cisplatin in the treatment of patients with NSCLC can significantly improve serum microRNA-19, TGF-beta 1, MMP2 levels, so as to achieve the purpose of improving the therapeutic effect.